TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05964543
Drug: Q-1802 Injection,Oxaliplatin Injection,Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
Study: NCT05860465
Drug: SPH4336 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
Study: NCT05860465
Drug: SPH4336 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
Study: NCT04650217
Drug: Carbidopa/levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose.
Study: NCT04650217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa matched placebo
Study: NCT06209879
Drug: SYSTANE™ Hydration Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
Study: NCT05178862
Drug: Echinocandin
Normalized name: Echinocandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous echinocandin
Study: NCT05849519
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was treated with conventional treatment
Study: NCT05687513
Drug: Yisui granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yisui granule
Study: NCT05687513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05547789
Drug: non steroidal anti inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of non steroidal anti inflammatory drugs on macular changes
Study: NCT04826016
Drug: POL6326
Approvals — FDA: no, EMA: no, PMDA: no
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study: NCT05126628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 tablets q.d. for 14 days
Study: NCT06429566
Drug: GB001 recombinant peptide spray low dose group、high dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
Study: NCT06429566
Drug: GB001 recombinant peptide spray placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
Study: NCT05377580
Drug: Period 1 IBI112 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT05377580
Drug: Period 2 IBI112 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT06635681
Drug: combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease.
Study: NCT05104970
Drug: SunnyD insta ampoule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 200000 IU insta ampoule
Study: NCT05104970
Drug: Placebo SunnyD insta ampoule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil
Study: NCT06580236
Drug: B11-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT05559645
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of DZD9008 200mg
Study: NCT05559645
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of DZD9008 300mg
Study: NCT04684121
Drug: Granexin® gel (200 μM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
Study: NCT04684121
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
Study: NCT06249932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Study: NCT06647550
Drug: HD-6277 100mg
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT06647550
Drug: HD-6277 50mg
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT06647550
Drug: HD-6277 25mg
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT06647550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT05050656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets identical to duloxetine tablets
Study: NCT05433597
Drug: TNF
Normalized name: TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
Study: NCT05433597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
Study: NCT04724967
Drug: CeraVe Hydrating Cleanser
Normalized name: CeraVe Hydrating Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cleanser applied twice a day for 28 days
Study: NCT04724967
Drug: CeraVe Moisturizing Cream
Normalized name: CeraVe Moisturizing Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream applied twice a day for 28 days
Study: NCT05346653
Drug: SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: dapagliflozin (10 mg daily)
Study: NCT06039358
Drug: Cellulose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Study: NCT04878913
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 was administered in the VP-C21-006 trial
Study: NCT04878913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered in the VP-C21-006 trial
Study: NCT04897854
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
Study: NCT06551259
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline
Study: NCT05800275
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m², twice daily on days 1-14 of each 21-day cycle
Study: NCT06471530
Drug: TE-8105 SAD Cohort 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
Study: NCT06471530
Drug: TE-8105 SAD Cohort 5 (Adaptive cohort)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
Study: NCT06471530
Drug: TE-8105 MAD Cohort 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.
Study: NCT06471530
Drug: TE-8105 MAD Cohort 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)
Study: NCT06471530
Drug: TE-8105 SAD Cohort 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.
Study: NCT06471530
Drug: TE-8105 SAD Cohort 4
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
Study: NCT06724900
Drug: 0.9% Normal Saline (NS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06732323
Drug: ESG401
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on day 1,8, and 15 of each 28 day cycle
Study: NCT06732323
Drug: Investigator's Choice Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
Study: NCT06732232
Drug: CD19/CD20/BCMA CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19/CD20/BCMA CAR T therapy
Study: NCT05591027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
Study: NCT06135103
Drug: talfirastide
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
Study: NCT06135103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
Study: NCT04494126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
Study: NCT05282797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05134181
Drug: sacroiliac joint injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied
Study: NCT05927259
Drug: n acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
Study: NCT05150938
Drug: Low molecular weight heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study: NCT05150938
Drug: vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
Study: NCT05927259
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: stabilization and antidotes
Study: NCT04620252
Drug: Tricalcium phosphate supplement
Normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tricalcium phosphate supplement, chewed for 30 seconds.
Study: NCT04620252
Drug: Calcium carbonate supplement
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable calcium carbonate supplement, chewed for 30 seconds.
Study: NCT04620252
Drug: Calcium citrate supplement
Normalized name: Calcium Citrate
DrugBank: Calcium Phosphate (DB11348)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable calcium citrate supplement, chewed for 30 seconds.
Study: NCT04620252
Drug: Calcium carbonate supplement and fluoride mouthwash
Normalized name: calcium carbonate / sodium fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study: NCT04620252
Drug: Calcium citrate supplement and fluoride mouthwash
Normalized name: sodium fluoride Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study: NCT04736628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06548932
Drug: GZR33 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose
Study: NCT06548932
Drug: GZR101 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose
Study: NCT06548932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose
Study: NCT06200883
Drug: Placebo oral vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
Study: NCT06200883
Drug: Choline Bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
Study: NCT05830071
Drug: CHF5993
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB 100/6/12.5 μg pMDI
Study: NCT05830071
Drug: CHF5259
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB 12.5 μg pMDI
Study: NCT05830071
Drug: CHF5993 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pMDI
Study: NCT06366230
Drug: Urea in the dialysate
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
Study: NCT06429800
Drug: ATA3219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
Study: NCT05972993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
Study: NCT05451654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Study: NCT05451654
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
Study: NCT06580288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg or 20mg
Study: NCT06485817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.
Study: NCT05788497
Drug: Hemorrane plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
Study: NCT05788497
Drug: Hemorrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemorrane 10 mg/g rectal ointment
Study: NCT05788497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ointment
Study: NCT06564441
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine
Study: NCT04677972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo containing excipients
Study: NCT05387577
Drug: Estradiol Tablets
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
Study: NCT05387577
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol patch therapy for 8 weeks
Study: NCT05387577
Drug: Estradiol Tablets
Normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral estradiol 1 mg BID for 8 weeks
Study: NCT04861077
Drug: [18F]FMISO-PET with contrast-enhanced MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
Study: NCT06520618
Drug: Qing Re He Ji
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Qing Re He Ji
Study: NCT06520618
Drug: Shuanghuanglian Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Shuanghuanglian Oral Liquid
Study: NCT04731779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Study: NCT06490562
Drug: PDCy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
Study: NCT06490562
Drug: Non Cy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
Study: NCT05812157
Drug: Anti-IL-17 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both groups will be on anti-IL-17 therapy
Study: NCT06636877
Drug: BR1019
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06636877
Drug: BR1019-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06523673
Drug: second-line systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen